Elevated serum endostatin levels are associated with favorable outcome in acute myeloid leukemia

Hematology

Volumn 13, Issue 2, 2008, Pages 95-100

  Aref, Salah ^a   El Sherbiny, M ^b   Azmy, E ^a   Goda, T ^a   Selim, T ^a   El Refaie, M ^c   Twafik, E ^a  

^a MANSOURA UNIVERSITY   (Egypt)

^b NATIONAL CANCER INSTITUTE   (Egypt)

^c MENOUFIA UNIVERSITY   (Egypt)

Author keywords

AML; Angiogenesis; Endostatin; Prognosis

Indexed keywords

ENDOSTATIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LEUKOCYTE COUNT; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SURVIVAL TIME; THROMBOCYTE COUNT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ENDOSTATINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 48749127489     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453308X315898     Document Type: Article

References (22)

1. Risau W. Mechanisms of angiogenesis. Nature 1997; 336: 671-674.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
3. O'Reilly MS, Boehm T, Shing Y et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
4. Felbor U, Dreier L, Bryant RAR, Ploegh HL, Olsen Rk, Mothes W. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 2000; 19: 1187-1194.
5. Halfter W, Dong S, Schurer B, Cole GJ. Collagen XVIII is a basement membrane heparan sulfate proteoglycan. J Biol Chem, 1998; 273: 25404-25412.
6. Dhanabal M, Ramchandran R, Waterman MJ et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 1999; 274: 11721-11726.
7. Lai R, Estey E, Shen Y et al. Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome. Cancer, 2002; 94: 14-17.
8. Wrobel T, Mazur G, Kapelko K, Kuliczkowski K. Endostatin serum level in acute myeloid leukemia. Neoplasma 2005; 52: 182-184.
9. Aguayo A, Estey E, Kantarjian H et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999; 94: 3717-3721.
10. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood, 2000; 95: 309-313.
11. Glenjen N, Mosevoll KA, Bruserud O. Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia. Int J Cancer, 2003; 101: 86-94.
12. Grimwade D, Walker H, Oliver F et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322-2333.
13. Bertolini F, Paolucci M, Peccatori F et al. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol 1999; 106: 504-509.
14. Bertolini F, Fusetti L, Mancuso P et al. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. Blood 2000; 96: 282-287.
15. Gora-Tybor J, Blonski JZ, Robak T. Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia. Mediators of Inflammation 2003; 12: 167-171.
16. Folkman J, Kalluri R. Cancer without disease. Nature, 2004; 427: 787-789.
17. Kumar S, Witzig TE, Timm M et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: Evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood, 2004; 104: 1159-1165.
18. Teh SH, Hill AD, Lee AW et al. Raised plasma endostatin levels correlate inversely with breast cancer angiogenesis. J Surg Res 2004; 116: 165-171.
19. Bruserud O, Glenjen N, Ryningen A. Effects of angiogenic regulators on in vitro proliferation and cytokine secretion by native human acute myelogenous leukemia blasts. Eur J Haematol 2003; 71: 9-17.
20. Jung SP, Siegrist B, Hornick CA et al. Effect of human recombinant Endostatin protein on human angiogenesis. Angiogenesis, 2002; 5: 111-118.
21. Schuch G, Heymach JV, Nomi M et al. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endotheial progenitor cells. Cancer Res 2003; 63: 8345-8350.
22. Schuch G, Oliveira-Ferrer L, Loges S et al. Antiangiogenic treatment with endostatin inhibits progression of AML in vivo. Leukemia, 2005; 19: 1312-1317.